| scholarly article | Q13442814 |
| P2093 | author name string | Matthew J Bull | |
| Nigel T Plummer | |||
| P2860 | cites work | Intestinal microbiota, probiotics and mental health: from Metchnikoff to modern advances: Part I – autointoxication revisited | Q21198785 |
| Intestinal microbiota, probiotics and mental health: from Metchnikoff to modern advances: Part II – contemporary contextual research | Q21198786 | ||
| Antibiotics and probiotics in inflammatory bowel disease: why, when, and how | Q22242719 | ||
| Probiotics for the prevention of pediatric antibiotic-associated diarrhea | Q24235039 | ||
| Probiotics for induction of remission in ulcerative colitis | Q24242963 | ||
| Intestinal microbiota, probiotics and mental health: from Metchnikoff to modern advances: part III – convergence toward clinical trials | Q24600527 | ||
| From NAFLD in clinical practice to answers from guidelines | Q27000185 | ||
| Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial | Q28211907 | ||
| Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials | Q28242365 | ||
| Low diversity of the gut microbiota in infants with atopic eczema | Q28254907 | ||
| Fecal microbiota transplantation and emerging applications | Q28255756 | ||
| Fecal bacteriotherapy for recurrent Clostridium difficile infection | Q28259539 | ||
| Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis | Q28266275 | ||
| Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea | Q28269350 | ||
| A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence | Q28295210 | ||
| Microbiota and SCFA in lean and overweight healthy subjects | Q29615812 | ||
| Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability | Q29617378 | ||
| Review article: prebiotics in the gastrointestinal tract | Q33254445 | ||
| Inulin and oligofructose: what are they? | Q33680999 | ||
| Decreased fat storage by Lactobacillus paracasei is associated with increased levels of angiopoietin-like 4 protein (ANGPTL4) | Q33711961 | ||
| Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. | Q33978896 | ||
| In vitro activity and fecal concentration of rifaximin after oral administration | Q33980321 | ||
| Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. | Q34006689 | ||
| The 'hygiene hypothesis' for autoimmune and allergic diseases: an update | Q34111851 | ||
| Prebiotic effects: metabolic and health benefits | Q34141652 | ||
| Bacterial probiotic modulation of dendritic cells | Q34144168 | ||
| Prebiotics and synbiotics: towards the next generation | Q34161876 | ||
| PROBIOTICS: GROWTH-PROMOTING FACTORS PRODUCED BY MICROORGANISMS. | Q34258740 | ||
| Increase in emergency admissions to hospital for children aged under 15 in England, 1999-2010: national database analysis | Q34327325 | ||
| Probiotics in man and animals | Q34505006 | ||
| Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease | Q34517039 | ||
| The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial | Q34574085 | ||
| Probiotics as functional food in the treatment of diarrhea | Q34575535 | ||
| Role of probiotics in correcting abnormalities of colonic flora induced by stress | Q34583797 | ||
| A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease | Q34588311 | ||
| Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects | Q34624664 | ||
| Probiotic effects on cold and influenza-like symptom incidence and duration in children | Q40383184 | ||
| Effects of feeding a probiotic preparation (SIM) containing inulin on the severity of colitis and on the composition of the intestinal microflora in HLA-B27 transgenic rats | Q40833729 | ||
| Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro | Q42282244 | ||
| An open-label evaluation of rifaximin in the treatment of active Crohn's disease | Q42664365 | ||
| Probiotics for Crohn's disease: what have we learned? | Q42844641 | ||
| Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects | Q42918043 | ||
| Probiotics reduce the risk of necrotising enterocolitis (NEC) in preterm infants | Q44547012 | ||
| Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study | Q46680959 | ||
| Molecular characterisation of the faecal microbiota in patients with type II diabetes | Q46864209 | ||
| In vitro evaluation of the antimicrobial activity of a range of probiotics against pathogens: evidence for the effects of organic acids. | Q50023399 | ||
| Probiotics to adolescents with obesity: effects on inflammation and metabolic syndrome | Q51355563 | ||
| Bifidobacterium longum supplementation improved high-fat-fed-induced metabolic syndrome and promoted intestinal Reg I gene expression | Q51371855 | ||
| Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study | Q52930916 | ||
| Probiotic yogurt for the treatment of minimal hepatic encephalopathy | Q53134638 | ||
| Lactobacillus species prevents colitis in interleukin 10 gene–deficient mice | Q59120727 | ||
| Rifaximin for active ulcerative colitis | Q59541334 | ||
| Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles | Q59880418 | ||
| Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice | Q59881087 | ||
| Effects of transgalactosylated disaccharides on the human intestinal microflora and their metabolism | Q72577356 | ||
| Administration of transgalacto-oligosaccharides increases fecal bifidobacteria and modifies colonic fermentation metabolism in healthy humans | Q73179536 | ||
| Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice | Q77659986 | ||
| Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice | Q79810116 | ||
| Benefits of a synbiotic formula (Synbiotic 2000Forte) in critically Ill trauma patients: early results of a randomized controlled trial | Q80286495 | ||
| Probiotics: definition, sources, selection, and uses | Q80463721 | ||
| Probiotics affect virulence-related gene expression in Escherichia coli O157:H7 | Q34627560 | ||
| Effect of Lactobacillus salivarius Ls-33 on fecal microbiota in obese adolescents | Q34627842 | ||
| Dietary inulin affects the expression of intestinal enterocyte iron transporters, receptors and storage protein and alters the microbiota in the pig intestine | Q34687504 | ||
| Inulin and oligofructose in the dietary fibre concept | Q34712413 | ||
| Probiotics: a novel approach in the management of food allergy | Q34738168 | ||
| The Bifidogenic Nature of Chicory Inulin and Its Hydrolysis Products | Q34744398 | ||
| The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review | Q34906850 | ||
| Fecal microbiota transplantation: facts and controversies | Q35044957 | ||
| Necrotizing enterocolitis: the evidence for use of human milk in prevention and treatment | Q35856821 | ||
| Benefits of lifestyle modification in NAFLD. | Q36172840 | ||
| Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases | Q36281405 | ||
| Probiotics, Prebiotics, and Synbiotics: Gut and Beyond | Q36282616 | ||
| Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases | Q36533648 | ||
| Quorum sensing by enteric pathogens | Q36667559 | ||
| Probiotic effects on inflammatory bowel disease. | Q36740877 | ||
| Prebiotics: the concept revisited | Q36740886 | ||
| Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birthweight: a systematic review of randomised controlled trials | Q36820897 | ||
| Diet, microbes, and host genetics: the perfect storm in inflammatory bowel diseases | Q36973376 | ||
| Antimicrobial-associated risk factors for Clostridium difficile infection | Q37051298 | ||
| Host factors in amniotic fluid and breast milk that contribute to gut maturation | Q37106314 | ||
| Necrotizing enterocolitis: a multifactorial disease with no cure | Q37136941 | ||
| Antibiotic-associated diarrhea: epidemiology, trends and treatment | Q37277087 | ||
| What's new in atopic eczema? An analysis of systematic reviews published in 2007 and 2008. Part 1. Definitions, causes and consequences of eczema | Q37623888 | ||
| Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens | Q37692838 | ||
| Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates | Q37733964 | ||
| The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus | Q37910974 | ||
| Food Formats for Effective Delivery of Probiotics | Q37963031 | ||
| Probiotics, prebiotics infant formula use in preterm or low birth weight infants: a systematic review | Q38038697 | ||
| Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease | Q38071415 | ||
| Intestinal Microbiota and its Role in Irritable Bowel Syndrome (IBS) | Q38098478 | ||
| Effect of nutrient supplementation on atopic dermatitis in children: a systematic review of probiotics, prebiotics, formula, and fatty acids | Q38107488 | ||
| Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice | Q38337680 | ||
| Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial | Q39109399 | ||
| Probiotic administration in early life, atopy, and asthma: a meta-analysis of clinical trials. | Q39364772 | ||
| Surface-layer protein extracts from Lactobacillus helveticus inhibit enterohaemorrhagic Escherichia coli O157:H7 adhesion to epithelial cells. | Q40240873 | ||
| G-CSF-mediated inhibition of JNK is a key mechanism for Lactobacillus rhamnosus-induced suppression of TNF production in macrophages | Q40247336 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dysbiosis | Q269334 |
| gastrointestinal system disease | Q2300099 | ||
| P304 | page(s) | 25-33 | |
| P577 | publication date | 2015-02-01 | |
| P1433 | published in | Integrative Medicine | Q15756796 |
| P1476 | title | Part 2: Treatments for Chronic Gastrointestinal Disease and Gut Dysbiosis | |
| P478 | volume | 14 |
| Q47640046 | Butyrate enhances mitochondrial function during oxidative stress in cell lines from boys with autism. |
| Q39113167 | Evolutionary and ecological forces that shape the bacterial communities of the human gut. |
| Q47194149 | Modulation of Immunological Pathways in Autistic and Neurotypical Lymphoblastoid Cell Lines by the Enteric Microbiome Metabolite Propionic Acid |
| Q30363954 | Modulation of mitochondrial function by the microbiome metabolite propionic acid in autism and control cell lines. |
| Q28075770 | The Significance of the Enteric Microbiome on the Development of Childhood Disease: A Review of Prebiotic and Probiotic Therapies in Disorders of Childhood |
Search more.